Oslo, October 22, 2021 - Observe Medical ASA (OSE: OBSRV) continues its rollout
of Sippi®, and reports clinical implementation at several sites in Europe -
including use outside intensive care units, and clinical evaluations driving the
health economic value of Sippi®

"We are excited to see Sippi® implementation gaining momentum as society and
hospitals now open up. This is a validation of the strong interest and our
customers appreciation of the clinical and health economic value of Sippi", says
Bjorn Larsson, CEO Observe Medical.

Significant developments are ongoing in a range of markets:

  · Italy: The implementation of Sippi® connected to the PDMS system Digistat®
in a major Italy hospital progresses well alongside the ongoing pilot clinical
use. This is coordinated by our distribution partner SIM Italia.
  · Finland: A clinical site using Sippi® since several years will now connect
their Sippi® systems in the Intensive Care Unit to their PDMS system.
  · Poland: Observe Medical's distributing partner, Skamex, recently held a
successful pre-launch event of Sippi® at a major intensive care conference in
Poland, and in November Sippi® will be introduced to several reference clinics
in Poland.
  · Sweden: At Nya Karolinska Hospital in Stockholm Sippi® will be implemented
at the Intermediary ward later this year. This is an example of how the use of
Sippi® is expanding outside Intensive care (ICU) departments at hospitals.

"Sippi® ongoing build-up of health economic evidence strongly supports an
outstanding clinical and economic value for patients and the healthcare system,
by using Sippi® compared to current manual urine monitoring systems. This is the
case with regards to reduced risk for infections, reduced cost of staff and
opportunities for early detection of severe clinical complications such as Acute
Kidney Injury (AKI)", Bjorn Larsson continues.

At Nya Karolinska Hospital in Stockholm Sweden, the ongoing study to evaluate
Sippi® for early detection of AKI (Acute Kidney Injury) progresses with a target
of 60 patients enrolled at the end of 2021. AKI is affecting more than 50% of
patients at ICU departments and represents a significant clinical burden to
patients and healthcare systems. Sippi® potential positive effect on early
detection of AIK is thus driving significant health economic value of Sippi®

Sippi® is the only automated digital urine meter with possibility for wireless
data transfer to the hospital patient data management systems and hinders
biofilm formation that can lead to urinary infections. Observe Medical is
currently executing on the go-to-market strategy for Sippi® with focus on the
clinical rollout in the Nordics and in selected European countries. Enhanced
distribution and market access, gathering of clinical evidence and experience
from pilot users is emphasized in this phase.

"As the COVID-19 pandemic situation gradually improves we experience enhanced
customers access for Observe Medical and our distribution partners. The
increased momentum of Sippi® in clinical use is exciting and we expect further
acceleration of the clinical rollout", Bjorn Larsson concludes.

For further information, please contact:
Björn Larsson, CEO, mobile: +46 76 620 17 25 E-mail:
bjorn.larsson@observemedical.com

About Observe Medical https://observemedical.com/
Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders bacterial migration that can lead to urinary infections
(SippCoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.